Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner
Aymeric Zadoroznyj(Medicon Village), Gottfrid Sjödahl(Lund University), Carl-Adam Mattsson(Lund University), Peter C. Black(University of British Columbia), Lena Tran(Medicon Village), Thomas W. Flaig(University of Colorado Denver), R diger Seiler(Spitalzentrum Centre hospitalier Biel- Bienne), David J. McConkey(University of Rochester Medicine), Pontus Eriksson(Lund University), Catherine M. Tangen(Fred Hutch Cancer Center), Fredrik Liedberg(Lund University), Carina Bernardo(Lund University), Seth P. Lerner(Baylor College of Medicine), Mattias Höglund(Lund University)
Cited by 0
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
A Molecular Taxonomy for Urothelial Carcinoma
|Clinical Cancer Research|2012|1k